Fulcrum Therapeutics (FULC) Price & Analysis

Compare

518 Followers

FULC Stock Chart & Stats

$10.23

-$0.39(-7.98%)

At close: Jan 08 4:00 PM EST

$10.23

-$0.39(-7.98%)

Day’s Range― - ―

52-Week Range$2.32 - $15.74

Previous CloseN/A

Volume345.04K

Average Volume (3M)764.07K

Market Cap

$674.88M

Enterprise Value$512.39M

Total Cash (Recent Filing)$200.65M

Total Debt (Recent Filing)$7.01M

Price to Earnings (P/E)―

Beta0.92

Next Earnings

Feb 26, 2026

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.31

Shares Outstanding65,970,290

10 Day Avg. Volume991,518

30 Day Avg. Volume764,071

Financial Highlights & Ratios

PEG Ratio0.33

Price to Book (P/B)1.20

Price to Sales (P/S)3.64

P/FCF Ratio-116.72

Enterprise Value/Market Cap0.76

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-765.90

Enterprise Value/Ebitda-7.07

Forecast

1Y Price Target

$16.80

Price Target Upside64.22% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPhase 1b PIONEER data showed a clear dose-response with a higher dose producing substantial fetal hemoglobin increases and early trends toward fewer painful vaso-occlusive crises, supporting clinical benefit beyond biomarker changes.

Commercial PotentialStrong early efficacy signals in a severely affected patient population, combined with high unmet need for sickle cell treatments, support a larger-than-expected market opportunity and have prompted upward valuation revisions by analysts.

Safety ProfileThe higher dose cohort was generally well tolerated with no treatment-related serious adverse events or dose-limiting toxicities reported, reducing safety concerns for broader development.

Bears Say

Analyst ConflictThe reporting firm's ongoing business and investment banking relationships with the company may create perceived conflicts of interest that could undermine confidence in published analysis and investor trust.

Efficacy ConcernsSome analysts highlight that the observed hemoglobin response was lower than expected compared with prior results, raising questions about the magnitude of disease modification and commercial differentiation.

Regulatory UncertaintyRegulatory discretion over label expansion and guidance-driven changes have pushed commercialization expectations into the later part of the decade, introducing timing risk for approval and revenue generation.

Fulcrum Therapeutics News

JPMorgan large/SMid cap biotech analysts hold analyst/industry conference call

Biotech Analysts provide insights into the evolving Sickle Cell Disease landscape, AGIO/FULC on an Analyst/Industry conference call to...

2d ago

AGIO

FULC

De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on FULC stock, giving a Buy rating on...

17d ago

FULC

Fulcrum Therapeutics updates strategy on lead sickle cell therapy

An announcement from Fulcrum Therapeutics ( ($FULC) ) is now available. On January 12, 2026, Fulcrum Therapeutics updated...

1M ago

FULC

Fulcrum Therapeutics initiated with an Overweight at JPMorgan

JPMorgan initiated coverage of Fulcrum Therapeutics (FULC) with an Overweight rating and $20 price target The recent Phase...

1M ago

FULC

Fulcrum Therapeutics price target raised to $18 from $14 at Truist

Truist raised the firm’s price target on Fulcrum Therapeutics (FULC) to $18 from $14 and keeps a Buy...

2M ago

FULC

Fulcrum Therapeutics Announces $175 Million Public Offering

Fulcrum Therapeutics ( ($FULC) ) has shared an announcement. On December 10, 2025, Fulcrum Therapeutics announced the pricing...

2M ago

FULC

Fulcrum Therapeutics 11.85M share Secondary priced at $13.50

The deal size was increased to $175M from $150M and priced below last closing price of $14.60. JPMorgan,...

2M ago

FULC

Fulcrum Therapeutics price target raised to $7 from $6 at BofA

BofA raised the firm’s price target on Fulcrum Therapeutics (FULC) to $7 from $6 and keeps an Underperform...

2M ago

FULC

Cautious Outlook for Fulcrum Therapeutics Amidst PIONEER Study Challenges and Market Uncertainties

In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Sell rating on Fulcrum...

2M ago

FULC

Fulcrum Therapeutics announces $150M offering of common stock

Fulcrum Therapeutics (FULC) announced that it has commenced an underwritten public offering of $150M of shares of its...

2M ago

FULC

Fulcrum Therapeutics price target raised to $25 from $20 at Stifel

Stifel raised the firm’s price target on Fulcrum Therapeutics (FULC) to $25 from $20 and keeps a Buy...

2M ago

FULC

Fulcrum Therapeutics price target raised to $24 from $15 at Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Fulcrum Therapeutics (FULC) to $24 from $15...

2M ago

FULC

Fulcrum Therapeutics price target raised to $10 from $7 at RBC Capital

RBC Capital raised the firm’s price target on Fulcrum Therapeutics (FULC) to $10 from $7 and keeps a...

2M ago

FULC

Fulcrum Therapeutics Reports Positive Phase 1b Trial Results

Fulcrum Therapeutics ( ($FULC) ) just unveiled an announcement. On December 6, 2025, Fulcrum Therapeutics announced positive initial...

2M ago

FULC

FULC FAQ

What was Fulcrum Therapeutics’s price range in the past 12 months?

Fulcrum Therapeutics lowest stock price was $2.31 and its highest was $15.74 in the past 12 months.

What is Fulcrum Therapeutics’s market cap?

Fulcrum Therapeutics’s market cap is $674.88M.

When is Fulcrum Therapeutics’s upcoming earnings report date?

Fulcrum Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 14 days.

How were Fulcrum Therapeutics’s earnings last quarter?

Fulcrum Therapeutics released its earnings results on Oct 29, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.294 by -$0.016.

Is Fulcrum Therapeutics overvalued?

According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fulcrum Therapeutics pay dividends?

Fulcrum Therapeutics does not currently pay dividends.

What is Fulcrum Therapeutics’s EPS estimate?

Fulcrum Therapeutics’s EPS estimate is -0.3.

How many shares outstanding does Fulcrum Therapeutics have?

Fulcrum Therapeutics has 65,970,290 shares outstanding.

What happened to Fulcrum Therapeutics’s price movement after its last earnings report?

Fulcrum Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.294. Following the earnings report the stock price went down -6.4%.

Which hedge fund is a major shareholder of Fulcrum Therapeutics?

Currently, no hedge funds are holding shares in FULC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Fulcrum Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-31.21%

Trailing 12-Months

Asset Growth

-22.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics (FULC) Earnings & Revenues

Historic Earnings Reports

FULC Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress in the clinical development of pociredir for sickle cell disease, with promising trial results and a strong financial position. Despite a decrease in cash reserves and continued net losses, the company's achievements and future plans position it well for further advancements.View all FULC earnings summaries

FULC Stock 12 Month Forecast

Average Price Target

$16.80

▲(64.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.72,11.81846153846154,12.916923076923077,14.015384615384615,15.113846153846154,16.212307692307693,17.310769230769232,18.409230769230767,19.50769230769231,20.606153846153845,21.704615384615387,22.803076923076922,23.90153846153846,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.72,11.18769230769231,11.655384615384616,12.123076923076924,12.590769230769231,13.05846153846154,13.526153846153846,13.993846153846155,14.461538461538462,14.92923076923077,15.396923076923077,15.864615384615385,16.332307692307694,{"y":16.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.72,10.433846153846154,10.147692307692308,9.861538461538462,9.575384615384616,9.28923076923077,9.003076923076923,8.716923076923077,8.430769230769231,8.144615384615385,7.858461538461539,7.572307692307692,7.286153846153846,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.7,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.87,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 52, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.72,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >